Expert Interviews

Panelists discuss how expanding CAR T therapy into earlier lines of multiple myeloma treatment requires careful evaluation of clinical trial data, infrastructure readiness, patient selection criteria, and manufacturing capacity while balancing the therapy’s potential benefits against established treatment approaches.

This video episode explores data supporting ide-cel in the second-line setting for multiple myeloma, highlighting key findings from the KarMMa and KarMMa-3 trials, comparisons to other options, and clinical experiences regarding efficacy, quality of life benefits, and implementation challenges.

Panelists discuss how successful comanagement of CAR T-cell therapy cases requires close coordination between academic centers and community practices, with structured protocols for monitoring, communication, and patient handoffs, while addressing challenges in referral timing, resource allocation, and long-term follow-up care.

Panelists discuss how effective co-management of chimeric antigen receptor (CAR) T patients requires clear communication protocols, standardized handoff procedures, and ongoing collaboration between academic centers and community practices to ensure safe transitions and optimal long-term monitoring.

Panelists discuss collaborating with community practices on CAR T-cell therapy for multiple myeloma through joint clinical trials, patient education programs, and shared data initiatives. These partnerships enhance treatment access, foster innovation, and improve patient outcomes across diverse settings.

“It does appear like MET expression could be one of the mechanisms wherein you could differentiate between responders and non-responders,” Kanwal P.S. Raghav, MBBS, MD, stated.

Panelists discuss how the evolving treatment landscape for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) is being shaped by emerging data on optimal treatment sequencing strategies, both in frontline settings and subsequent lines of therapy.

Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Dr. Garon discusses his approach to selecting between available EGFR inhibitors for treating EGFR+ NSCLC.

“Frozen section is destructive. It ruins the tissue, it consumes the tissue, and it affects downstream molecular analysis,” according to Farzad Fereidouni, PhD.

Panelists discuss areas for improvement in the RCC journey from the patient perspective, including the impact of emerging research on their experience, and explore therapeutic approaches and clinical research areas that show promise for improving outcomes in advanced RCC, with a focus on novel targets and mechanisms of action in development.

Panelists discuss their institution’s multidisciplinary approach to RCC care, emphasizing key specialties involved in coordinating patient care, ensuring seamless collaboration and communication across the team, the value of a multidisciplinary care team from the patient perspective, and unmet needs or opportunities to enhance supportive care and quality of life for patients with RCC, including gaps in education and practical ways nurses can empower and support patients.

Anant Madabhushi, PhD, stated that MarginCall, a surgery tool he is developing can improve patient outcomes in breast and ovarian cancer surgeries.

TRAQinform IQ provides spatial and temporal information for each lesion from serial PET/CT scans, helping to inform the next steps for cancer treatment.

In this segment, Dr. Mohan asks Dr. Mann to summarize the key efficacy data from the MagnestisMM trials evaluating the use of elranatamab in relapsed/refractory multiple myeloma (R/R MM).

The FIBI technology, created by Farzad Fereidouni, PhD, when combined with AI eliminates the need for frozen sections and other labor-intensive oncology surgery practices.

Panelists discuss how PALOMA-3, a phase 3 randomized clinical trial, was designed to evaluate subcutaneous vs intravenous amivantamab, both in combination with lazertinib, in patients with refractory EGFR–mutated non–small cell lung cancer.

Panelists discuss how managing adverse events and selecting optimal treatment strategies remain key challenges in front-line EGFR-mutated, non–small cell lung cancer (mNSCLC) therapy, particularly when weighing the efficacy and toxicity profiles of available targeted therapies.